Press Releases

U.S. Army Advances Lead COVID-19 Vaccine Candidate

A U.S. Army laboratory, the Walter Reed Army Institute of Research, a subordinate command of the Army Futures Command’s Medical Research and Development Command, announced the selection of a lead COVID-19 vaccine candidate a two backup vaccine candidates that will advance to the next stage of research. The candidates were narrowed down from more than two dozen prototypes in order to determine the candidates that elicited the most promising antibody response in preclinical studies.

Minimal SARS-CoV-2 Diversity Suggests a Global Vaccine is Feasible

NOTE: This press release was updated on August 31 to reflect the publication of the manuscript in a peer review journal.

Genetic analysis of sequences from more than 27,000 individuals infected with the coronavirus that causes COVID-19 reveals that the virus has mutated minimally since December 2019, suggesting one vaccine would be sufficient to combat global infections.

Understanding the Initial Immune Response after Dengue Virus Infection

A study led by scientists at the Walter Reed Army Institute of Research sheds new light on the body’s initial response to dengue virus (DENV) infection, describing the molecular diversity and specificity of the antibody response.  These results, published in EBioMedicine, a journal published by The Lancet, identify a heretofore unappreciated role for DENV-reactive IgA antibodies. 

Army-developed Zika Vaccine Induces Potent Zika and Dengue Cross-neutralizing Antibodies

A new study led by scientists at the Walter Reed Army Institute of Research has shown for the first time that a single dose of an experimental Zika vaccine in a dengue-experienced individual can boost pre-existing flavivirus immunity and elicit protective cross-neutralizing antibody responses against both Zika and dengue viruses. Findings were published today in Nature Medicine.